4:15 a.m. March 17, 2021
Startup behind AstraZeneca vaccine raises millionsLONDON -- The Oxford startup behind AstraZeneca PLC's Covid-19 vaccine has raised $168 million in new funding, which it plans to use to adopt its vaccine technology for the treatment of other diseases.
2:41 p.m. March 7, 2021
IPO for Oxford COVID-19 vaccine startup in perilA startup behind the Covid-19 vaccine developed by the University of Oxford and AstraZeneca PLC is planning an initial public offering that backers hope will be the biggest market debut of an Oxford spinoff in years.
4:17 a.m. Dec. 10, 2020
- By Ciara Linnane
Gilead to acquire Germany's MYR GmbH for EUR1.15 billion in cash Gilead Sciences Inc. said Thursday it has agreed to acquire MYR GmbH, a German biotech, for 1.15 billion euros ($1.39 billion) in cash, plus a potential future milestone payment of up to 300 million euros. The milestone payment will be made upon FDA approval of MYR's hepcludex, a treatment for chronic HDV infection in adults with compensated liver disease that has won conditional approval from the European Medicines Agency. HDV is the most severe form of viral hepatitis. "Hepcludex is a first-in-class treatment for HDV that blocks viral entry into liver cells through binding to NTCP," Gilead said in a statement. "It is the first and currently the only medicine conditionally approved for HDV by the EMA, and MYR anticipates submission for accelerated approval in the United States in the second half of 2021." The drug has both orphan drug and breakthrough therapy designations from the FDA. Gilead is expecting the deal to enhance revenue, be neutral to EPS in the first two years and then modestly accretive. Gilead shares were slightly higher premarket, but have fallen 6% in the year to date, while the SPDR S&P Biotech ETF has gained 44% and the S&P 500 has gained 13.7%.
12:30 p.m. Sept. 13, 2020
Gilead reaches $21 billion deal for ImmunomedicsGilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of the cancer-drugs business. Immunomedics has a market value of roughly $10 billion following a recent surge in its stock, meaning that Gilead is paying up to secure ownership of the company.
12:29 p.m. Sept. 13, 2020
AstraZeneca COVID-19 vaccine trials resumeAstraZeneca PLC said Saturday clinical trials for its experimental coronavirus vaccine have resumed in the U.K. after regulators concluded it was safe to do so, following a pause in studies globally after a person who received the vaccine had an unexplained illness.
12:58 a.m. Aug. 10, 2020
- By Sherri Snelling
Could flu vaccines lower your risk of Alzheimer’s? Research sheds new light Two studies released at the Alzheimer’s Association conference indicate a possible connection between flu and pneumonia shots with reducing or delaying cognitive declineThe studies show ‘vaccines are strongly associated with lower prevalence of dementia,’ says one scientist.
2:13 a.m. July 31, 2020
- By Jaimy Lee
Gilead swings to a big loss on acquisition expense, stock falls after earnings and revenue miss The drugmaker expects to produce more than 2 million courses of COVID-19 treatment remdesivir by the end of the yearShares of Gilead Sciences Inc. fell more than 1% in after-hours trading Thursday after the drugmaker reported that it swung to a large loss during the second quarter and missed estimates even after adjusting for an acquisition.
2:11 a.m. June 30, 2020
- By Jaimy Lee
Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not The drugmaker’s decision to price remdesivir below expectations could be a ‘promising sign’ of how much other COVID-19 treatments will cost, said one expertGilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured, responsible approach to the pharmaceutical pricing of treatments and vaccines during the pandemic.
10:06 a.m. June 29, 2020
- By Jaimy Lee
Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed ‘People, companies are starting to plan to make doses even before, you know, the vaccine works,’ Dr. Anthony Fauci said Tuesday on Capitol HillInovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
3:44 a.m. May 1, 2020
- By Jaimy Lee
Gilead expects to spend up to $1 billion on coronavirus drug this year, will donate 1.5 million vials CEO says Gilead ‘could charge for’ remdevisir, but donating entire supply through early summer ‘is the right thing to do at this time’Gilead Sciences Inc. reported better-than-expected earnings for the first quarter of the year on Thursday and detailed more of its work on remdesivir, an antiviral COVID-19 drug candidate.
8:43 a.m. April 30, 2020
- By Jaimy Lee
The pandemic has shifted focus to remdesivir, but HIV drugs will return to center stage for Gilead Gilead in the age of COVID-19: Investors will pay close attention to what the company says about what’s next for its experimental drug remdesivir, as well as its HIV portfolio and oncology ambitionsIf this pandemic is going to have a savior, investors are betting that Gilead Sciences Inc. is their personal Jesus.
5:50 a.m. April 23, 2020
- By Joseph E. Stiglitz
Should patents come before patients? How drug monopolies hamper the fight against coronavirus COVID-19 pandemic shows the urgency of replacing a monopoly-driven system with one based on cooperation and shared knowledgeDrug monopolies kill, by denying access to life-saving medicines that otherwise would have been available under an alternative system — like the one facilitating the yearly production of the flu vaccine.